Literature DB >> 18230796

Re: UGT1A1*28 genotype and irinotecan-induced neutropenia: dose matters.

Wataru Ichikawa, Kazuhiro Araki, Ken-ichi Fujita, Wataru Yamamoto, Hisashi Endo, Fumio Nagashima, Ryuhei Tanaka, Toshimichi Miya, Keiji Kodama, Yu Sunakawa, Masaru Narabayashi, Yuichi Ando, Yuko Akiyama, Kaori Kawara, Yasutsuna Sasaki.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2008        PMID： 18230796     DOI： 10.1093/jnci/djm302

Source DB:  PubMed          Journal:  J Natl Cancer Inst        ISSN： 0027-8874            Impact factor:   13.506


× No keyword cloud information.
  4 in total

1.  Indispensability of UGT1A1*6 genotyping in Japanese cancer patients treated with irinotecan.

Authors:  Masashi Takano; Masafumi Kato; Tomoyuki Yoshikawa; Tomoko Goto; Kenichi Furuya; Yoshihiro Kikuchi
Journal:  Int J Clin Oncol       Date:  2010-02-24       Impact factor: 3.402

Review 2.  Role of Genetic Polymorphisms in Drug-Metabolizing Enzyme-Mediated Toxicity and Pharmacokinetic Resistance to Anti-Cancer Agents: A Review on the Pharmacogenomics Aspect.

Authors:  Gera Narendra; Shalki Choudhary; Baddipadige Raju; Himanshu Verma; Om Silakari
Journal:  Clin Pharmacokinet       Date:  2022-09-30       Impact factor: 5.577

Review 3.  Irinotecan, a key chemotherapeutic drug for metastatic colorectal cancer.

Authors:  Ken-ichi Fujita; Yutaro Kubota; Hiroo Ishida; Yasutsuna Sasaki
Journal:  World J Gastroenterol       Date:  2015-11-21       Impact factor: 5.742

4.  Value of plasma SN-38 levels and DPD activity in irinotecan-based individualized chemotherapy for advanced colorectal cancer with heterozygous type UGT1A1*6 or UGT1A1*28.

Authors:  Chuan Tian; Haifeng Ying; Rongyuan Zhuang; Xiaowei Zhang; Hongmin Lu; Hui Wang; Shuowen Wang; Qi Li; Chungang Wang; Xun Cai
Journal:  Cancer Manag Res       Date:  2018-11-22       Impact factor: 3.989
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.